Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis
NCT00123149 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2016-09-20
Summary
The purpose of this study is to evaluate the long-term safety profile of epoetin alfa in patients with anemia of chronic disease due to rheumatoid arthritis
Conditions
Interventions
- DRUG
-
Epoetin alfa
Sponsors & Collaborators
-
Ortho Biotech Products, L.P.
lead INDUSTRY
Principal Investigators
-
Ortho Biotech Products, L.P. Clinical Trial · Ortho Biotech Products, L.P.
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Completion
- 2007-10-31
More Related Trials
-
A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia
NCT00228995 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.
NCT00212875 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.
NCT00210756 ·Status: COMPLETED ·Phase: PHASE2
-
Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa
NCT00210626 ·Status: TERMINATED ·Phase: PHASE2
-
Treatment of Anemia in Diabetic Subjects With CKD
NCT00240734 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease
NCT00641589 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Chronic Anemia With Epoetin Alfa in Elderly
NCT00337441 ·Status: UNKNOWN ·Phase: PHASE2
-
PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
NCT00440466 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin
NCT00210951 ·Status: COMPLETED
-
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
NCT00258440 ·Status: TERMINATED ·Phase: NA
-
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia
NCT00002042 ·Status: COMPLETED ·Phase: NA
-
An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease
NCT01846689 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
NCT01290328 ·Status: TERMINATED ·Phase: NA
-
A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients
NCT00246298 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant Erythropoietins
NCT00211029 ·Status: COMPLETED
-
A First Human Study of a Ferroportin Antibody
NCT01330953 ·Status: COMPLETED ·Phase: PHASE1
-
The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic
NCT00002303 ·Status: COMPLETED ·Phase: NA
-
Treatment Program for Anemia in AIDS Patients
NCT00002022 ·Status: COMPLETED ·Phase: NA
-
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
NCT00002072 ·Status: COMPLETED ·Phase: NA
-
Erythropoietin to Improve Critical Care Patient Outcomes
NCT05080049 ·Status: UNKNOWN ·Phase: PHASE3
-
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy
NCT00002073 ·Status: COMPLETED ·Phase: NA
-
Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia
NCT00954486 ·Status: WITHDRAWN ·Phase: NA
-
A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
NCT00446602 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)
NCT00317902 ·Status: COMPLETED ·Phase: PHASE4
-
Predictors of Response to Iron and Erythropoietin Stimulating Agents
NCT03658876 ·Status: COMPLETED ·Phase: PHASE4